X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
iTOL-102 is our lead program that is developed Using our proprietary SA-FasL biotin-PEG microgel platform, which being developed as a potential cure for Type 1 Diabetes without the need for chronic immunosuppression.
Lead Product(s): Allogeneic Stem Cell-derived Pancreatic Islets
Therapeutic Area: Endocrinology Product Name: iTOL-102
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: iTolerance
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2023
Details:
Under the agreement, Kadimastem will supply its advanced cell product, IsletRx and iTolerance will provide its iTOL-100 immunomodulatory technology for the development of iTOL-102 (allogenic pancreatic islet cell) for the treatment of Type 1 Diabetes.
Lead Product(s): Allogenic Pancreatic Islet Cell
Therapeutic Area: Endocrinology Product Name: iTOL-102
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: iTolerance
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 18, 2023
Details:
Kadimastem’s flagship product, AstroRx®, is comprised of a differentiated cell population of human astrocytes derived from human pluripotent stem cells and is in clinical development as a therapeutic treatment for ALS.
Lead Product(s): Human pluripotent stem cells
Therapeutic Area: Neurology Product Name: AstroRx
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
Details:
The primary objective of the trial was to evaluate the safety of AstroRx®, an "off-the-shelf", clinical-grade, astrocyte cell product, developed and manufactured by the Company. The trial met its endpoints.
Lead Product(s): Human astrocytes
Therapeutic Area: Neurology Product Name: AstroRx
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Details:
Kadimastem's lead product, AstroRx®, showed a positive efficacy signal and a good safety profile in Cohort B of the Company’s Phase 1/2a clinical trial in ALS.
Lead Product(s): Human astrocytes
Therapeutic Area: Neurology Product Name: AstroRx
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
A statistically significant decline in disease progression was observed during the first 3- 4 months post-treatment period, indicating a clinical benefit of the AstroRx® cell product.
Lead Product(s): AstroRx
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
